晚期结肠癌的治疗选择主要是化疗和靶向药物的组合。然而，身体健康不佳和药物不耐受限制了抗癌药物的选择。肝硬化并发结肠癌是一类对临床治疗构成挑战的特殊患者群体。本文介绍了一例处于失代偿期的肝硬化患者，被诊断为晚期结肠癌。最初的表现是脐部的一颗结节，名为Sister Mary Joseph's结节，经活检和PET-CT确认为结肠癌的转移灶之一。患者接受了奥曲肽和5-氟尿嘧啶低于指导剂量的治疗，然而出现了门静脉血栓形成并导致死亡。从诊断到死亡的整个过程发生在三个月内。肝硬化并发癌症是一个应该引起更多关注的特殊群体。这些患者没有统一的治疗指南，特别是那些有肝外原发肿瘤的患者。以后在选择这类患者的治疗时应更加谨慎。化疗和靶向治疗都可能诱发门静脉血栓形成，其发生率似乎比没有肝硬化的癌症更高，预后更差。© 2023. BioMed Central Ltd., part of Springer Nature.

Treatment options for advanced colon cancer are mainly combinations of chemotherapy and targeted drugs. However, poor physical health and medication intolerance limit the choice of anticancer drugs. Colon cancer with cirrhosis is a particular patient group that poses a challenge to clinical treatment.This article presents a case of a patient in the decompensated stage of cirrhosis who was diagnosed with advanced colon cancer. The initial presentation was a nodule on his navel named the Sister Mary Joseph's nodule, which was later confirmed by biopsy and PET-CT as one of the metastases of colon cancer. The patient was treated with cetuximab and 5-fluorouracil at a below-guideline dose; however, portal vein thrombosis developed and led to death. This entire process, from diagnosis to death, occurred within a span of three months.Cancers with cirrhosis are a special group that deserves more attention. There is no unified treatment guideline for these patients, especially those with extrahepatic primary tumors. We should be more cautious when choosing treatment for such patients in the future. Both chemotherapy and targeted treatment may potentially induce portal vein thrombosis, which appears to have a higher incidence and worse prognosis than cancers without cirrhosis.© 2023. BioMed Central Ltd., part of Springer Nature.